Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
59
DRUG Quote, Financials, Valuation and Earnings
Last price:
$78.74
Seasonality move
:
-24.59%
Day range:
$75.11 - $80.90
52-week range:
$23.18 - $97.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.31x
Volume:
323.1K
Avg. volume:
164.2K
1-year change:
116.66%
Market cap:
$607.7M
Revenue:
--
EPS (TTM):
-$1.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-- | -$1.02 | -- | -472.01% | $105.39 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
$78.04 | $105.39 | $607.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.64 | $0.85 | $710.7M | 9.47x | $0.80 | 0% | 10.96x |
|
NNVC
NanoViricides, Inc.
|
$1.13 | $6.50 | $20.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.78 | $2.00 | $644.5K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
0.15% | 0.424 | 0.02% | 35.50x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-$12.3K | -$4.1M | -24.31% | -24.38% | -- | -$946.3K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Bright Minds Biosciences, Inc. vs. Competitors
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -255.85%. Bright Minds Biosciences, Inc.'s return on equity of -24.38% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.41 $59.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences, Inc. has a consensus price target of $105.39, signalling upside risk potential of 35.05%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that Bright Minds Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Bright Minds Biosciences, Inc.'s net income of -$3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3M NBYNovaBay Pharmaceuticals, Inc.10.96x 9.47x $521K -$1.3M
-
Which has Higher Returns DRUG or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -24.38% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.41 $59.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About DRUG or NNVC?
Bright Minds Biosciences, Inc. has a consensus price target of $105.39, signalling upside risk potential of 35.05%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 475.22%. Given that NanoViricides, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe NanoViricides, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.6 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is DRUG or NNVC More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock DRUG or NNVC?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NNVC?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns DRUG or OGEN?
Oragenics, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -24.38% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.41 $59.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About DRUG or OGEN?
Bright Minds Biosciences, Inc. has a consensus price target of $105.39, signalling upside risk potential of 35.05%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 155.36%. Given that Oragenics, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Oragenics, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.6 0 0 OGENOragenics, Inc.1 0 0 -
Is DRUG or OGEN More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock DRUG or OGEN?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or OGEN?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns DRUG or PTN?
Palatin Technologies has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -24.38% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.41 $59.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DRUG or PTN?
Bright Minds Biosciences, Inc. has a consensus price target of $105.39, signalling upside risk potential of 35.05%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.6 0 0 PTNPalatin Technologies0 0 0 -
Is DRUG or PTN More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DRUG or PTN?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or PTN?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3M is higher than Palatin Technologies's net income of --. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DRUG or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -24.38% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.41 $59.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About DRUG or TOVX?
Bright Minds Biosciences, Inc. has a consensus price target of $105.39, signalling upside risk potential of 35.05%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3227%. Given that Theriva Biologics, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.6 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DRUG or TOVX More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock DRUG or TOVX?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or TOVX?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
